Company intelligence / Profile preview

Q Therapeutics

Salt Lake City, Utah, United Statesqthera.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Q Therapeutics is advancing a novel human glial progenitor cell therapy platform. Its lead product candidate, Q‑Cells®, has received FDA IND clearance to begin a Phase 1/2a clinical trial in Transverse Myelitis. The company has also received Orphan Drug designation from the FDA for ALS and is progressing toward clinical trials in additional neurodegenerative diseases. Preclinical data support potential efficacy across multiple demyelinating and neurodegenerative conditions.

Therapeutic areas: Neurology
Modalities: Human glial progenitor cell therapyAdult stem cells
Industry: Biotech

Drug pipeline

1 asset

Q-Cells

Partnerships

Cephalon/Teva Pharmaceuticals ($3.7M equity investment)National Institutes of Health grant funding ($4M+)University of Utah Research Foundation

Beyond the preview

Go deeper on Q Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q Therapeutics.

Explore the full profile